US20030054048A1 - Method of increasing the presence of glutathione in cells - Google Patents
Method of increasing the presence of glutathione in cells Download PDFInfo
- Publication number
- US20030054048A1 US20030054048A1 US10/284,158 US28415802A US2003054048A1 US 20030054048 A1 US20030054048 A1 US 20030054048A1 US 28415802 A US28415802 A US 28415802A US 2003054048 A1 US2003054048 A1 US 2003054048A1
- Authority
- US
- United States
- Prior art keywords
- glutathione
- enhancer
- group
- extract
- picrorhiza
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 title claims abstract description 356
- 229960003180 glutathione Drugs 0.000 title claims abstract description 174
- 108010024636 Glutathione Proteins 0.000 title claims abstract description 147
- 230000001965 increasing effect Effects 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 title claims description 15
- 239000003623 enhancer Substances 0.000 claims abstract description 88
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 40
- 239000000203 mixture Substances 0.000 claims abstract description 37
- 230000021615 conjugation Effects 0.000 claims abstract description 35
- 230000001404 mediated effect Effects 0.000 claims abstract description 35
- 229930013686 lignan Natural products 0.000 claims abstract description 32
- 235000009408 lignans Nutrition 0.000 claims abstract description 32
- 150000005692 lignans Chemical class 0.000 claims abstract description 32
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 27
- 230000008929 regeneration Effects 0.000 claims abstract description 27
- 238000011069 regeneration method Methods 0.000 claims abstract description 27
- 235000018417 cysteine Nutrition 0.000 claims abstract description 24
- 239000002243 precursor Substances 0.000 claims abstract description 24
- 206010019670 Hepatic function abnormal Diseases 0.000 claims abstract description 12
- 241000124008 Mammalia Species 0.000 claims abstract description 5
- 239000000284 extract Substances 0.000 claims description 65
- DFYRUELUNQRZTB-UHFFFAOYSA-N apocynin Chemical compound COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 claims description 35
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 33
- 238000002360 preparation method Methods 0.000 claims description 33
- 235000005911 diet Nutrition 0.000 claims description 32
- 230000000378 dietary effect Effects 0.000 claims description 31
- 241001470615 Picrorhiza Species 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 29
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 claims description 28
- 235000010841 Silybum marianum Nutrition 0.000 claims description 28
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 claims description 27
- 235000001014 amino acid Nutrition 0.000 claims description 26
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 241001470703 Picrorhiza kurrooa Species 0.000 claims description 24
- 235000017700 silymarin Nutrition 0.000 claims description 23
- 229960004245 silymarin Drugs 0.000 claims description 23
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 22
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 22
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 22
- 229910052711 selenium Inorganic materials 0.000 claims description 22
- 239000011669 selenium Substances 0.000 claims description 22
- 235000011649 selenium Nutrition 0.000 claims description 22
- 240000006079 Schisandra chinensis Species 0.000 claims description 21
- 244000272459 Silybum marianum Species 0.000 claims description 19
- 239000004480 active ingredient Substances 0.000 claims description 17
- 229930188866 apocynin Natural products 0.000 claims description 17
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 16
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 claims description 13
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 13
- 235000019152 folic acid Nutrition 0.000 claims description 12
- 239000011724 folic acid Substances 0.000 claims description 12
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 11
- 229930182817 methionine Natural products 0.000 claims description 11
- 229940011671 vitamin b6 Drugs 0.000 claims description 11
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 10
- 229960000304 folic acid Drugs 0.000 claims description 10
- 229930003779 Vitamin B12 Natural products 0.000 claims description 9
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 9
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 9
- 235000019163 vitamin B12 Nutrition 0.000 claims description 9
- 239000011715 vitamin B12 Substances 0.000 claims description 9
- 235000019158 vitamin B6 Nutrition 0.000 claims description 9
- 239000011726 vitamin B6 Substances 0.000 claims description 9
- 229930182489 iridoid glycoside Natural products 0.000 claims description 8
- 150000008145 iridoid glycosides Chemical class 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 239000011787 zinc oxide Substances 0.000 claims description 8
- 229960004643 cupric oxide Drugs 0.000 claims description 7
- 229930195126 picroside Natural products 0.000 claims description 7
- 229940024606 amino acid Drugs 0.000 claims description 6
- 150000001879 copper Chemical class 0.000 claims description 6
- 150000002696 manganese Chemical class 0.000 claims description 6
- 235000014012 manganese gluconate Nutrition 0.000 claims description 6
- 239000011683 manganese gluconate Substances 0.000 claims description 6
- 229940072543 manganese gluconate Drugs 0.000 claims description 6
- OXHQNTSSPHKCPB-IYEMJOQQSA-L manganese(2+);(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Mn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OXHQNTSSPHKCPB-IYEMJOQQSA-L 0.000 claims description 6
- 150000003751 zinc Chemical class 0.000 claims description 6
- 241000736075 Schisandra Species 0.000 claims 25
- 239000007787 solid Substances 0.000 claims 24
- 239000004615 ingredient Substances 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 15
- 241000700159 Rattus Species 0.000 description 13
- 102000006587 Glutathione peroxidase Human genes 0.000 description 11
- 108700016172 Glutathione peroxidases Proteins 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 241000320380 Silybum Species 0.000 description 10
- 239000003963 antioxidant agent Substances 0.000 description 10
- 235000006708 antioxidants Nutrition 0.000 description 10
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 9
- 229960004308 acetylcysteine Drugs 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 229960005489 paracetamol Drugs 0.000 description 9
- 239000011701 zinc Substances 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 8
- 206010067125 Liver injury Diseases 0.000 description 8
- 102000019197 Superoxide Dismutase Human genes 0.000 description 8
- 108010012715 Superoxide dismutase Proteins 0.000 description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 8
- XSIQHIDJSCQWBB-QHJBZRDQSA-N [(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] 3-methoxy-4-[(E)-3-phenylprop-2-enoyl]oxybenzoate dihydrate Chemical compound O.O.COc1cc(ccc1OC(=O)\C=C\c1ccccc1)C(=O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XSIQHIDJSCQWBB-QHJBZRDQSA-N 0.000 description 8
- 239000010949 copper Substances 0.000 description 8
- 229910052802 copper Inorganic materials 0.000 description 8
- 231100000234 hepatic damage Toxicity 0.000 description 8
- 230000008818 liver damage Effects 0.000 description 8
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 8
- -1 thiyl radicals Chemical class 0.000 description 8
- 229910052725 zinc Inorganic materials 0.000 description 8
- 244000163122 Curcuma domestica Species 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 7
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 7
- 102000004316 Oxidoreductases Human genes 0.000 description 7
- 108090000854 Oxidoreductases Proteins 0.000 description 7
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 7
- 244000269722 Thea sinensis Species 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 235000003373 curcuma longa Nutrition 0.000 description 7
- 238000001784 detoxification Methods 0.000 description 7
- 239000003053 toxin Substances 0.000 description 7
- 231100000765 toxin Toxicity 0.000 description 7
- 108700012359 toxins Proteins 0.000 description 7
- 102000005720 Glutathione transferase Human genes 0.000 description 6
- 108010070675 Glutathione transferase Proteins 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 6
- 230000002440 hepatic effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 230000002443 hepatoprotective effect Effects 0.000 description 5
- 229910052748 manganese Inorganic materials 0.000 description 5
- 239000011572 manganese Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 108010053070 Glutathione Disulfide Proteins 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- FDQAOULAVFHKBX-UHFFFAOYSA-N Isosilybin A Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC(=CC=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-UHFFFAOYSA-N 0.000 description 4
- 244000042664 Matricaria chamomilla Species 0.000 description 4
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 4
- VLGROHBNWZUINI-UHFFFAOYSA-N Silybin Natural products COc1cc(ccc1O)C2OC3C=C(C=CC3OC2CO)C4Oc5cc(O)cc(O)c5C(=O)C4O VLGROHBNWZUINI-UHFFFAOYSA-N 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 150000001765 catechin Chemical class 0.000 description 4
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 4
- 235000005487 catechin Nutrition 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229960002477 riboflavin Drugs 0.000 description 4
- 229940043175 silybin Drugs 0.000 description 4
- 235000014899 silybin Nutrition 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 235000003392 Curcuma domestica Nutrition 0.000 description 3
- RTZKSTLPRTWFEV-OLZOCXBDSA-N Deoxygomisin A Chemical compound COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3C[C@@H](C)[C@@H](C)CC2=CC2=C1OCO2 RTZKSTLPRTWFEV-OLZOCXBDSA-N 0.000 description 3
- 108010063907 Glutathione Reductase Proteins 0.000 description 3
- RTZKSTLPRTWFEV-UHFFFAOYSA-N Isokadsuranin Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3CC(C)C(C)CC2=CC2=C1OCO2 RTZKSTLPRTWFEV-UHFFFAOYSA-N 0.000 description 3
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 3
- 235000006468 Thea sinensis Nutrition 0.000 description 3
- AKNILCMFRRDTEY-NUGKWEEESA-N [(1as,1bs,2s,5ar,6s,6as)-1a-(hydroxymethyl)-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,5a,6,6a-tetrahydro-1bh-oxireno[5,6]cyclopenta[1,3-c]pyran-6-yl] 4-hydroxy-3-methoxybenzoate Chemical compound C1=C(O)C(OC)=CC(C(=O)O[C@H]2[C@H]3[C@H]([C@@H](OC=C3)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@@]3(CO)O[C@H]32)=C1 AKNILCMFRRDTEY-NUGKWEEESA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000012754 curcumin Nutrition 0.000 description 3
- 239000004148 curcumin Substances 0.000 description 3
- 229940109262 curcumin Drugs 0.000 description 3
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 3
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000009569 green tea Nutrition 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- AKNILCMFRRDTEY-UHFFFAOYSA-N picroside II Natural products C1=C(O)C(OC)=CC(C(=O)OC2C3C(C(OC=C3)OC3C(C(O)C(O)C(CO)O3)O)C3(CO)OC32)=C1 AKNILCMFRRDTEY-UHFFFAOYSA-N 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000019192 riboflavin Nutrition 0.000 description 3
- 239000002151 riboflavin Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000013976 turmeric Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 241001483116 Neopicrorhiza scrophulariiflora Species 0.000 description 2
- 241000224017 Plasmodium berghei Species 0.000 description 2
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- JANLDILJJLTVDB-UHFFFAOYSA-N [6-hydroxy-2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,5a,6,6a-tetrahydro-1bh-oxireno[5,6]cyclopenta[1,3-c]pyran-1a-yl]methyl 4-hydroxy-3-methoxybenzoate Chemical compound C1=C(O)C(OC)=CC(C(=O)OCC23C(O2)C(O)C2C3C(OC3C(C(O)C(O)C(CO)O3)O)OC=C2)=C1 JANLDILJJLTVDB-UHFFFAOYSA-N 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229960001570 ademetionine Drugs 0.000 description 2
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 2
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 2
- 229940117893 apigenin Drugs 0.000 description 2
- 235000008714 apigenin Nutrition 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 235000000639 cyanocobalamin Nutrition 0.000 description 2
- 239000011666 cyanocobalamin Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 231100000776 exotoxin Toxicity 0.000 description 2
- 239000002095 exotoxin Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 229940014144 folate Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 231100000334 hepatotoxic Toxicity 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229930182491 iridoid glucoside Natural products 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000008160 pyridoxine Nutrition 0.000 description 2
- 239000011677 pyridoxine Substances 0.000 description 2
- 229940074091 schisandra chinensis fruit extract Drugs 0.000 description 2
- 150000003342 selenium Chemical class 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- SEBFKMXJBCUCAI-WAABAYLZSA-N (2r,3r)-3,5,7-trihydroxy-2-[(2s,3s)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one Chemical compound C1=C(O)C(OC)=CC([C@H]2[C@@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-WAABAYLZSA-N 0.000 description 1
- QUOZWMJFTQUXON-UXXRCYHCSA-N 1-[3-methoxy-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]ethanone Chemical compound COC1=CC(C(C)=O)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QUOZWMJFTQUXON-UXXRCYHCSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 1
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
- QUOZWMJFTQUXON-UHFFFAOYSA-N Androsin Natural products COC1=CC(C(C)=O)=CC=C1OC1C(O)C(O)C(O)C(CO)O1 QUOZWMJFTQUXON-UHFFFAOYSA-N 0.000 description 1
- 241000208327 Apocynaceae Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 108010018763 Biotin carboxylase Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- QIIDATRCGITYRZ-UHFFFAOYSA-N Catalpol Natural products OCC1OC(OC2OC=CC3C(O)C(=C(CO)C23)O)C(O)C(O)C1O QIIDATRCGITYRZ-UHFFFAOYSA-N 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 239000005751 Copper oxide Substances 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- LNSXRXFBSDRILE-UHFFFAOYSA-N Cucurbitacin Natural products CC(=O)OC(C)(C)C=CC(=O)C(C)(O)C1C(O)CC2(C)C3CC=C4C(C)(C)C(O)C(O)CC4(C)C3(C)C(=O)CC12C LNSXRXFBSDRILE-UHFFFAOYSA-N 0.000 description 1
- CVKKIVYBGGDJCR-SXDZHWHFSA-N Cucurbitacin B Natural products CC(=O)OC(C)(C)C=CC(=O)[C@@](C)(O)[C@@H]1[C@@H](O)C[C@]2(C)C3=CC[C@@H]4C(C)(C)C(=O)[C@H](O)C[C@@]4(C)[C@@H]3CC(=O)[C@@]12C CVKKIVYBGGDJCR-SXDZHWHFSA-N 0.000 description 1
- YPWSLBHSMIKTPR-UHFFFAOYSA-N Cystathionine Natural products OC(=O)C(N)CCSSCC(N)C(O)=O YPWSLBHSMIKTPR-UHFFFAOYSA-N 0.000 description 1
- 108050008072 Cytochrome c oxidase subunit IV Proteins 0.000 description 1
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 description 1
- 101000844746 Drosophila melanogaster Drosomycin Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 102000004263 Glutamate-Cysteine Ligase Human genes 0.000 description 1
- 108010081687 Glutamate-cysteine ligase Proteins 0.000 description 1
- 108010036164 Glutathione synthase Proteins 0.000 description 1
- 102100034294 Glutathione synthetase Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- FYSHYFPJBONYCQ-OLZOCXBDSA-N Gomisin K3 Natural products O(C)c1c(OC)c2-c3c(O)c(OC)c(OC)cc3C[C@@H](C)[C@@H](C)Cc2cc1OC FYSHYFPJBONYCQ-OLZOCXBDSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 101000881168 Homo sapiens SPARC Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 241001113425 Iridaceae Species 0.000 description 1
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108090000279 Peptidyltransferases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 101000621511 Potato virus M (strain German) RNA silencing suppressor Proteins 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 102000004669 Protein-Lysine 6-Oxidase Human genes 0.000 description 1
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 description 1
- 108010053763 Pyruvate Carboxylase Proteins 0.000 description 1
- 102100039895 Pyruvate carboxylase, mitochondrial Human genes 0.000 description 1
- 102100037599 SPARC Human genes 0.000 description 1
- 241000736078 Schisandra sphenanthera Species 0.000 description 1
- 241000758724 Schisandraceae Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 206010042464 Suicide attempt Diseases 0.000 description 1
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 241001105470 Valenzuela Species 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- XZGPUOQGERGURE-LUVHZPKESA-N [(2r,3s,4s,5r,6s)-6-[[(1as,1bs,2s,5ar,6s,6as)-6-hydroxy-1a-(hydroxymethyl)-2,5a,6,6a-tetrahydro-1bh-oxireno[5,6]cyclopenta[1,3-c]pyran-2-yl]oxy]-3,4,5-trihydroxyoxan-2-yl]methyl (e)-3-phenylprop-2-enoate Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@H]1OC=C[C@H]2[C@H](O)[C@@H]3O[C@@]3([C@@H]12)CO)OC(=O)\C=C\C1=CC=CC=C1 XZGPUOQGERGURE-LUVHZPKESA-N 0.000 description 1
- 150000008062 acetophenones Chemical class 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 230000001929 anti-hepatotoxic effect Effects 0.000 description 1
- 230000000433 anti-nutritional effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229940085398 ascorbic acid 50 mg Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 125000000188 beta-D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- LHDWRKICQLTVDL-PZYDOOQISA-N catalpol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2C=CO1 LHDWRKICQLTVDL-PZYDOOQISA-N 0.000 description 1
- UXSACQOOWZMGSE-UHFFFAOYSA-N catalposide Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(OC(=O)C=3C=CC(O)=CC=3)C2C=CO1 UXSACQOOWZMGSE-UHFFFAOYSA-N 0.000 description 1
- 239000000731 choleretic agent Substances 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 229910000431 copper oxide Inorganic materials 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 150000001944 cysteine derivatives Chemical class 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- PIGAXYFCLPQWOD-UHFFFAOYSA-N dihydrocucurbitacin I Natural products CC12C(=O)CC3(C)C(C(C)(O)C(=O)CCC(C)(O)C)C(O)CC3(C)C1CC=C1C2C=C(O)C(=O)C1(C)C PIGAXYFCLPQWOD-UHFFFAOYSA-N 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- SCIGYBYAZUFDLA-YRWPAIAPSA-N globularin Natural products OC[C@H]1O[C@@H](O[C@@H]2OC=C[C@H]3[C@H](O)[C@@H]4O[C@]4(COC(=O)C=Cc5ccccc5)[C@@H]23)[C@H](O)[C@@H](O)[C@@H]1O SCIGYBYAZUFDLA-YRWPAIAPSA-N 0.000 description 1
- 102000010705 glucose-6-phosphate dehydrogenase activity proteins Human genes 0.000 description 1
- 108040005050 glucose-6-phosphate dehydrogenase activity proteins Proteins 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 229930186755 gomisin Natural products 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000784 hepatotoxin Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- FLRDKVYYXANFFA-SYAJEJNSSA-L manganese(2+);(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;dihydrate Chemical compound O.O.[Mn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FLRDKVYYXANFFA-SYAJEJNSSA-L 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- LHDWRKICQLTVDL-UHFFFAOYSA-N methyl iridoid glycoside Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2C=CO1 LHDWRKICQLTVDL-UHFFFAOYSA-N 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 238000012753 partial hepatectomy Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000004108 pentose phosphate pathway Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000003617 peroxidasic effect Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 1
- 238000009160 phytotherapy Methods 0.000 description 1
- KEUKDVIGAVVGLF-RUYHYXBRSA-N picroside I Natural products OC[C@]12O[C@H]1[C@@H]3O[C@@H](O[C@@H]4O[C@H](COC(=O)C=Cc5ccccc5)[C@@H](O)[C@H](O)[C@H]4O)C=C[C@@H]3[C@H]2O KEUKDVIGAVVGLF-RUYHYXBRSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 1
- FYSHYFPJBONYCQ-QWHCGFSZSA-N schisanhenol Chemical compound C1[C@H](C)[C@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2O FYSHYFPJBONYCQ-QWHCGFSZSA-N 0.000 description 1
- FYSHYFPJBONYCQ-UHFFFAOYSA-N schisanhenol Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2O FYSHYFPJBONYCQ-UHFFFAOYSA-N 0.000 description 1
- YBZZAVZIVCBPDJ-UHFFFAOYSA-N schizandrin B Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3CC(C)C(C)(O)CC2=CC2=C1OCO2 YBZZAVZIVCBPDJ-UHFFFAOYSA-N 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229940065287 selenium compound Drugs 0.000 description 1
- 150000003343 selenium compounds Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000621 toxification Toxicity 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 229940065804 vitamin b 12 1.3 mg Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
Definitions
- This invention relates to a method of increasing the presence of glutathione in cells including treating or preventing of impaired liver function by administering to a mammal in the need thereof a dietetic or pharmaceutical composition and to a corresponding dietetic or pharmaceutical composition.
- the liver is the major organ involved in metabolism of protein, carbohydrates, and fats, but is also the major organ for detoxification. Potential toxic compounds are converted into inactive metabolites by phase I-metabolising enzymes and excreted. Alternatively, metabolites are further conjugated by phase II-metabolising enzymes and excreted after all.
- Reduced glutathione is the substrate of glutathione peroxidase (GPX) and as such contributes to the antioxidant defence mechanism as well.
- Glutathione reductase enzymes reduce GSSG back to GSH, predominantly in the presence of NADPH, which is provided by e.g. the oxidative pentose phosphate pathway.
- the capacity of the glutathione system to cope with H 2 O 2 in liver depends on the activity of GPX and glutathione reductase, the rate of NADPH supply, and the GSH content.
- GSH can also react with e.g. OH°, HOCI, peroxynitrite, RO°, and RO 2 ° in vitro.
- thiyl radicals Upon reacting with free radicals, thiyl radicals (GS°) are produced, which generate superoxide.
- superoxide can also inactivate GPX in the absence of GSH.
- superoxide dismutase (SOD) or antioxidants can co-operate with GSH to remove free radicals in vivo.
- GST glutathione S-transferase enzymes
- GSH is synthesised in two steps, catalysed by two different enzymes.
- ⁇ -glutamylcysteine synthetase (GCS) catalyses the formation of L- ⁇ -glutamyl-L-cysteine from glutamate and cysteine.
- the second step incorporates glycine under influence of glutathione synthetase, yielding GSH.
- One example of a drug that can deplete the concentration of reduced glutathione in the liver is the commonly used sedative acetaminophen (paracetamol).
- Acetaminophen has caused severe hepatic necrosis when ingested in large amounts, e.g. in suicide attempts or accidentally by children.
- Acetaminophen hepatotoxicity is mediated by a toxic reactive metabolite formed from the parent compound by the cytochrome P450 mixed-function oxidase system of the hepatocyte. The metabolite is then detoxified by conjugation with glutathione.
- the glutathione reserves of the liver are depleted, and the quinonimine reacts with constituents of the liver cells, leading to necrosis.
- the hepatic injury may be potentiated by the use of alcohol or other drugs and also starvation and cachexia, conditions in which liver glutathione are lower, may potentiate the effect.
- Milk thistle, or Silybum marianum (L.) Gaertn. (Compositae) is in Western countries well-known for its hepatoprotective effects. Its key components are flavanolignans, collectively known as silymarin.
- a composition for the protection, treatment and repair of liver tissue containing Milk thistle is for instance described in WO 99/43336.
- silymarin The main component of silymarin, silybin, exerted inhibitory effects on superoxide and hydrogen peroxide production in human neutrophils and increased the activity of both superoxide dismutase and glutathione peroxidase in human erythrocytes
- Silymarin protects against acetaminophen-induced GSH depletion and cytotoxicity in hepatoblastoma Hep G2 cells in vitro.
- Silymarin and silybin protect in vivo against hepatic glutathione depletion induced by ethyl alcohol and paracetamol in rats.
- silybin reduces the GSH depletion induced by acetaminophen, but does not affect GSH depletion by buthionine sulfoximide in isolated rat hepatocytes. This suggests that it enhances GSH oxidation or conjugation, without affecting glutamylcysteine synthetase or GSH synthesis (Garrido et al., Pharmacology and Toxicology 69, 9-12 (1991)).
- silybin was found to be a potent, non-toxic, inhibitor of glutathione-S-transferase (Bartholomeus et al., Xenobiotica 24, 17-24, (1994)). This observation leads to the conclusion that, although silymarin might be effective as a hepatoprotective agent, secondary detoxification by conjugation to GSH, as is catalysed by GSH-transferase, is inhibited.
- Silymarin treatment (Legalon, 420 mg, 6 months) in patients with chronic alcoholic liver disease in a double blind placebo controlled trial increased the serum level of free —SH groups and the activity of GSH peroxidase.
- Other clinical trials confirm the hepatoprotective effect of standardised Silybum extracts.
- RO 102689 (Intr. Medic though Biofarm) discloses the extraction of silymarin from armurariu fruit. Said extract shall be useful in the treatment of active chronic hepatitis, cirrhosis of the liver and for the protection of liver cells during administration of hepatoxic agents.
- Picrorhiza kurrooa Royle (Scrophulariaceae) has been used in ⁇ overscore (A) ⁇ yurveda mainly for the treatment of liver disorders. Iridoid glucosides have been regarded as its active constituents; however, other compounds like acetophenones might also play a role.
- Picroliv is a standardised fraction of Picrorhiza kurrooa containing the iridoid glycosides picroside I and kutkoside in a ratio of 1:1.5 to 1:2 (50-70%) and a mixture of cucurbitacin glycosides (4-5%) (US-A 5145955).
- Picroside II has also been isolated from Picrorhiza kurrooa and 50 mg/kg p.o. in mice treated with CCl4 showed a hepatoprotective activity (DE-A 2203884).
- Picroliv has been tested in a number of liver damage models in vitro and in vivo. These studies have demonstrated its antihepatotoxic, hepatoregenerative, choleretic, and hypolipidemic activities (reviewed by Dhawan, Medicinal Chemistry Research 5, 595-605, (1995)). Hepatoregenerative effects were associated with an increased recovery of the liver anti-oxidant system after partial hepatectomy or carbon tetrachloride-induced liver damage of Picroliv-treated rats. Furthermore, Picroliv significantly reversed paracetamol-induced biochemical changes in several liver cell markers after oral administration to rats (6 and 12 mg/kg) for 7 days.
- Picroliv given to rats during the last 15 days (12 mg/kg/day p.o.) of a 45 days exposure to alcohol, prevented the decrease of superoxide dismutase, catalase, glutathione-S-transferase, and the level of reduced glutathione (Rastogi et al., 1196). Picroliv (6 mg/kg/day p.o.) recovered the depletion of reduced glutathione level and the inhibition of glutathione-S-transferase, glutathione reductase, and glutathione peroxidase activities in the livers of mice infected with Plasmodium berghei.
- Apocynin an acetophenone isolated from P. kurrooa, enhances intracellular GSH synthesis, mediated by the increased expression of ⁇ -GCS mRNA and enzyme activity through activation of transcription factor AP-1 (Lapperre et al., Febs Letters 443, 235-9, (1999)).
- Schisandra chinensis (Turcz.) Baill (Schisandraceae) is a winding herb found in the Far East. Its fruits have been used since long in traditional medicine in this part of the world.
- the main active ingredients are lignans, e.g. schisandrins (gomisins). These compounds were shown to be potent hepatoprotective agents (Hancke et al., Fitorick 70, 451-471, (1999)). They are able to enhance the GSH/GSSG ratio and the activity of GSH reductase, increasing the GSH status of liver cell mitochondria. Furthermore, they are able to enhance detoxification by enhancing cytochrome P450-mediated metabolism of hepatotoxins, followed by the induction of GSH-S-transferase-mediated conjugation.
- Schisandra chinensis extract (1.6 g/kg/day p.o.) increases hepatic GSH levels, GSH reductase and GSH-transferase activities and prevents liver damage in rats with aflatoxin- and cadmium-induced liver damage.
- Pretreatment of schisanhenol and schizandrin B (200 mg/kg) to mice with ethanol-induced liver peroxidation increased dismutase and catalase activity, while GSH-peroxidase activity was unaffected.
- the direct antioxidants are radical scavengers by their chemical composition or interfere with the formation of oxygen radicals.
- the antioxidants most commonly known for this function are vitamin C, vitamin E and flavonoids.
- Catechins from green tea and curcumin have similar effects and enhance the antioxidant activity.
- Selenium is a component of glutathione peroxidase in erythrocytes and other tissues. Glutathione peroxidase reduces hydrogen peroxide to water. Selenium is thought to be well-absorbed both as inorganic selenium salts and organic selenium compounds. A 200 ⁇ g/day supplement for 2 months in selenium-deficient patients with alcoholic cirrhosis significantly improved plasma selenium levels and glutathione peroxidase but had no effect on peroxidative parameters.
- Zinc has a role in protection against oxygen radical damage, being an essential component of cytoplasmic superoxide dismutase. Zinc ions also bind to sulphydryl groups in proteins, protecting them against oxidation. Most (80-85%) plasma zinc is bound to albumin, 15% to alpha2-macroglobulin and ⁇ 2% to RBP. Plasma zinc levels are depressed by infections and other stressors, probably due to systemic redistribution mediated by metallothionein, and perhaps because plasma albumin levels are reduced in stress.
- Copper is an essential part of many enzymes which are involved in protection against free radical damage, e.g. cytochrome oxidase, lysyl oxidase, Zn/Cu superoxide dismutase. About 30% of dietary copper is absorbed, and there is some evidence that this increases in deficiency. Dietary deficiency is extremely rare. Over 80% of plasma copper is bound to ceruloplasmin (a positive acute phase protein that increases in inflammatory conditions). Free copper ions (unlikely in normal conditions but may occur in the case of copper excess) are a major source of oxygen radicals.
- ceruloplasmin a positive acute phase protein that increases in inflammatory conditions.
- Manganese is part of a number of metalloenzymes, including mitochondrial pyruvate carboxylase, superoxide dismutase and acetyl CoA carboxylase.
- components are administered which are precursors for the endogenous glutathione production. Together therewith components are administered which enhance the endogenous glutathione biosynthesis and which enhance the regeneration of oxidised glutathione, and/or enhance the glutathione-mediated conjugation.
- the present invention provides a method of increasing the presence of glutathione in cells including the prevention or treatment of impaired liver function and novel dietetic or pharmaceutical compositions for said purpose comprising in combination at least a) one precursor of glutathione which is selected from the group consisting of cysteine and functional equivalents containing said amino acid, b) one enhancer of the glutathione biosynthesis, and c) a third component which is either selected from lignans or which is a combination c1) of an enhancer of glutathione regeneration and c2) of an enhancer of the glutathione-mediated conjugation.
- the method and the compositions of the present invention can treat and/or prevent the above mentioned diseases.
- the glutathione presence or the glutathione status, respectively, in the cells is increased or improved, respectively. This applies in particular for the treatment and/or prevention of impaired liver function.
- the present invention is applicable for mammals including human beings and animals, for instance birds.
- diseases here described can occur during intensive animal breeding due to the consumption of an unbalanced feed diet.
- Liver problems occur due to the excessive amount of fats of inferior quality or the consumption of waste products of the human food industry which for some reason have become contaminated or comprise too high levels of anti-nutritional factors. This happens predominantly in pig and poultry breeding.
- a glutathione precursor a) is administered in a certain minimum amount.
- Said precursor a) is either cysteine or one or more functional analogue(s) containing said amino acid cystelne or a combination of both.
- Said functional analogues are for instance salts and common esters of cysteine, especially of the L-isomer, N-alkylated derivatives of cysteine, such as N-acetyl cysteine (NAC), cysteine-rich proteins and peptides, such as some proteins from whey or egg, and cystathionine, both in reduced or oxidised form Glutathione itself in reduced or oxidised form can also increase glutathione tissue levels.
- cystein analogues When methionine or S-adenosylmethionine (SAM) are used as cystein analogues the risk for elevated cystein levels is high in animals including men suffering from impaired liver function.
- SAM S-adenosylmethionine
- said compounds are used as cystein analogues at least folic acid, vitamin B6 and/or zinc should be present in addition.
- Preferably all three compounds are present in amounts that exceed the recommended daily amounts.
- the Glutathione precursor used according to the invention can be a single species or a mixture of different components or species, respectively.
- the minimum amount of the precursor a) administered per day is at least 100 mg cysteine, calculated as free amino acid.
- the minimum amount is preferably at least 200 mg per day.
- the maximum amount of cysteine should not exceed 2000 mg.
- the absolute amounts of the equivalents can be easily calculated by using the molar weight of the above mentioned amino acid.
- the precursor of glutathione a) is administered together with an enhancer of the glutathione biosynthesis b) and together with a third component c) described below.
- a) b) and c) are administered or contained in the compositon of the invention.
- the third component c) administered is either one or more lignans or a combination of an enhancer of glutathione regeneration c1) and of an enhancer of the glutathione mediated conjugation c2).
- lignans can act as an enhancer of glutathione regeneration c1) as well as an enhancer of the glutathione mediated conjugation c2). Consequently, according to a first embodiment of the present invention, the third component c) can consist of one lignan alone or a mixture of different lignans.
- the third component c) can be a combination of one or more lignans either with one enhancer or more enhancers of the glutathione biosynthesis c1) which is or are different from a lignan, or with one enhancer or more enhancers of the gutathione-mediated conjugation c2) which is or are different from a lignan.
- the third component c) can be a combination of one enhancer or more enhancers of the glutathione biosynthesis c1) which is or are different from a lignan with one enhancer ore more enhancers of the gutathione-mediated conjugation c2) which is or are also different from a lignan.
- the third component c) can be a combination of i) one enhancer or more enhancers of the glutathione biosynthesis c1) which is or are different from a lignan, ii) one enhancer or more enhancers of the gutathione-mediated conjugation c2) which is or are also different from and of iii) one lignan or more lignans.
- the enhancer of the glutathione biosynthesis b) contains apocynin or analogues.
- Apocynin can be isolated from plants such as Iris species (Iridaceae) or from the rhizome of Apocynam cannabinum or other Apocynaceae.
- the enhancer of the glutathione biosynthesis b) is a preparation obtained from Picrorhiza species; even more preferably the enhancer of the glutathione biosynthesis b) is selected from the group consisting of an extract of Picrorhiza kurrooa and an extract of Picrorhiza schrophulariiflora, whereby said extract contains most preferably 0.01 to 100 mg per day apocynin or analogues.
- the enhancer of glutathione regeneration c1) is preferably selected from the group consisting of preparations rich in silymarin, such as extracts from Silybum marianum or armurariu fruit, and preparations rich in schisandrins, such as extracts from Schisandra species; and the enhancer of glutathione-mediated detoxification process c2) is preferably selected from the group consisting of preparations rich in iridoid glycosides, especially extracts from Picrorhiza species, and preparations rich in Schisandrins such as extracts from Schisandra species.
- the preparation of Picrorhiza species is preferably an extract from Picrorhiza kurrooa or Picrorhiza scrophulariiflora (also known as Neopicrorhiza scrophulariiflora ), which contains preferably 1-100 mg of total iridoid glycosides, in particular 1 to 100 mg picrosides, more preferably 1 to 50 mg picroside II, for example about 6 mg picroside II, and 0.01-100 mg apocynin.
- analogues of apocynin may be used instead of or in addition to apocynin.
- Such analogues are in particular those in which the 4-hydroxy group is etherified, especially with a sugar moiety.
- the analogue in which the sugar moiety is ⁇ -D-glucose is commonly known as androsin.
- the preparation of Silybum marianum is preferably an extract containing 10-1000 mg silymarin, more preferably 175 mg of an extract containing 140 mg of silymarin.
- the preparation of Schisandra species is preferably an extract from Schisandra chinensis or Schisandra sphenanthera containing 0.1-100 mg of lignans, in particular 0.1 to 100 mg schisandrins, more preferably 11 to 70 mg schisandrins, for example about 5 mg schisandrins.
- the different components a), b), c), c1), and, c2) are known and described above.
- herbs e.g. Milk thistle, Picrorhiza and Schisandra can be used, which are known to exhibit liver protective activities, and induce or enhance the endogenous glutathione production.
- This endogenous antioxidant plays a central role in the metabolisation and elimination of toxins.
- the GSH status in the liver is increased, and in addition, the enzyme ⁇ -glutamylcysteine synthetase, responsible for GSH synthesis, is enhanced as well.
- the present invention includes precursors and cofactors important for glutathione synthesis, compounds that enhance glutathione regeneration, and compounds that induce the glutathione-mediated detoxification process.
- direct antioxidants like vitamin C, E, and flavonoids, and enzymatic antioxidants like selenium, zinc, copper, and manganese enhancing the antioxidant activity of the liver can be present in addition according to the present invention.
- enzymatic antioxidants like selenium, zinc, copper, and manganese enhancing the antioxidant activity of the liver. This is preferred since several toxins are capable of exhibiting oxidative damage due to the formation of oxygen radicals.
- Enzymatic antioxidants are in particular components that improve the activity of glutathione peroxidase or superoxide dismutase.
- Selenium can be used as selenium salt and preferably as selenium yeast that provides per daily dose 10-200 mcg selenium.
- Zinc can be present as an inorganic or organic zinc salt, such as ZnO providing preferably 0.1-30 mg zinc per daily dose.
- Copper can be present as a copper salt, providing preferably 0.1-8 mg copper per daily dose.
- Manganese can be present as a manganese salt, providing preferably 0.1-20 mg manganese per daily dose.
- the composition can contain at least one compound that further enhances the glutathione status of the liver, as a cofactor in the biosynthesis of precursors of glutathione.
- a compound is selected from the group consisting of riboflavin, preferably 0.1-200 mg riboflavin, vitamin B66, preferably 0.1-200 mg vitamin B6, vitamin B12, preferably 0.1-3000 mcg vitamin B12. and folic acid or folate, preferably 10-1000 mcg folic acid.
- Preferred sources of vitamin B6 and vitamin B12 are pyridoxine and cyanocobalamine, respectively.
- the composition can contain at least one component that enhances the antioxidant function by directly scavenging reactive oxygen species or by interfering with their formation.
- a component is selected from the group consisting of vitamin C, preferably 10-1000 mg vitamin C, vitamin E, preferably 1-800 mg ⁇ -TE, flavonoids, preferably an extract of Matricaria recutita containing 1-100 mg apigenin, catechins, preferably an extract of Camellia sinensis containing 1-500 mg catechins, and curcuminoids, preferably an extract of Curcuma longa containing 1-1000 mg curcumin.
- the present invention applies also to animals and in particular to pig and poultry breeding.
- the components used according to the present invention can be present in the extracts of plants which are preferably used in animal feed. Said components can also be included in a premix for blending with regular animal feed.
- the premix is preferably based on whey proteins as source of the glutathione precursor a).
- compositions of the invention can have a form that is normally used for the administration of a food or of a food supplement. They can be present for instance as powders, liquids. emulsions, bars, tablets, and capsules which can be packaged in cartons, cans, sachets, bottles, bags (tea bags) and can be prepared according to methods known in the art.
- a composition according to the invention in the form of a tablet contains for instance 300 mg glutathione, 20 mg apocynin and 5 mg schisandrins.
- Three tablets were administered daily, preferably combined with an additional multivitamin, to treat deprived liver function.
- Amount per daily dose Amount unit Silybum marianum (milk thistle) 175 mg Picrorhiza kurrooa 120 mg vitamin B2 (riboflavin) 1.25 mg vitamin B6 (pyridoxine) 1.3 mg vitamin B12 premix (1% 0.18 mg cyanocobalamin) folic acid (monoglutamate) 200 mcg N-acetylcysteine 1000 mg
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
- This invention relates to a method of increasing the presence of glutathione in cells including treating or preventing of impaired liver function by administering to a mammal in the need thereof a dietetic or pharmaceutical composition and to a corresponding dietetic or pharmaceutical composition.
- The liver is the major organ involved in metabolism of protein, carbohydrates, and fats, but is also the major organ for detoxification. Potential toxic compounds are converted into inactive metabolites by phase I-metabolising enzymes and excreted. Alternatively, metabolites are further conjugated by phase II-metabolising enzymes and excreted after all.
- Many drugs and toxins can be detoxified by conjugation with glutathione. When the levels of these drugs or toxins, however, exceed the liver concentration of reduced glutathione; such components become acute hepatotoxic. Striking is that in several kinds of liver disorders, glutathione levels are decreased, for example: in hepatitis infection, where the grade of activity of the liver disease is correlated with reduction of GSH in acute liver toxification, e.g. acetaminophen intoxication, and in alcoholics with liver failure
- Both hepatitis C and the exposure to liver toxins can lead to hepatocarcinoma, possibly via the same mechanism of incompetence of the liver to respond to toxins, either endo-toxins or exo-toxins.
- Reduced glutathione (GSH) is the substrate of glutathione peroxidase (GPX) and as such contributes to the antioxidant defence mechanism as well.
- Glutathione reductase enzymes reduce GSSG back to GSH, predominantly in the presence of NADPH, which is provided by e.g. the oxidative pentose phosphate pathway. The capacity of the glutathione system to cope with H2O2 in liver depends on the activity of GPX and glutathione reductase, the rate of NADPH supply, and the GSH content. Except for its effects on hydrogen peroxide, GSH can also react with e.g. OH°, HOCI, peroxynitrite, RO°, and RO2° in vitro. Upon reacting with free radicals, thiyl radicals (GS°) are produced, which generate superoxide. Moreover, superoxide can also inactivate GPX in the absence of GSH. Hence, superoxide dismutase (SOD) or antioxidants can co-operate with GSH to remove free radicals in vivo.
- Many xenobiotics supplied to living organisms are metabolised by conjugation with GSH. This process is catalysed by glutathione S-transferase enzymes (GST).
- GSH is synthesised in two steps, catalysed by two different enzymes. During the first step, Υ-glutamylcysteine synthetase (GCS) catalyses the formation of L-Υ-glutamyl-L-cysteine from glutamate and cysteine. The second step incorporates glycine under influence of glutathione synthetase, yielding GSH.
- One example of a drug that can deplete the concentration of reduced glutathione in the liver is the commonly used sedative acetaminophen (paracetamol). Acetaminophen has caused severe hepatic necrosis when ingested in large amounts, e.g. in suicide attempts or accidentally by children. Acetaminophen hepatotoxicity is mediated by a toxic reactive metabolite formed from the parent compound by the cytochrome P450 mixed-function oxidase system of the hepatocyte. The metabolite is then detoxified by conjugation with glutathione. If excessive amounts are formed, the glutathione reserves of the liver are depleted, and the quinonimine reacts with constituents of the liver cells, leading to necrosis. The hepatic injury may be potentiated by the use of alcohol or other drugs and also starvation and cachexia, conditions in which liver glutathione are lower, may potentiate the effect.
- Milk thistle, orSilybum marianum (L.) Gaertn. (Compositae) is in Western countries well-known for its hepatoprotective effects. Its key components are flavanolignans, collectively known as silymarin. A composition for the protection, treatment and repair of liver tissue containing Milk thistle is for instance described in WO 99/43336.
- Intraperitoneal administration of silymarin (200 mg/kg) in rats increased the total glutathione content and improved the reduced glutathione/oxidised glutathione ratio in the liver, intestine, and stomach, while levels of kidney, lung, and spleen were not affected (Valenzuela et al/., Selectivity of silymarin on the increase of gutathione content in different tissues of the rat, Planta Medica 55, 420-2 (1989)). The main component of silymarin, silybin, exerted inhibitory effects on superoxide and hydrogen peroxide production in human neutrophils and increased the activity of both superoxide dismutase and glutathione peroxidase in human erythrocytes Silymarin protects against acetaminophen-induced GSH depletion and cytotoxicity in hepatoblastoma Hep G2 cells in vitro. Silymarin and silybin protect in vivo against hepatic glutathione depletion induced by ethyl alcohol and paracetamol in rats. It was shown that silybin reduces the GSH depletion induced by acetaminophen, but does not affect GSH depletion by buthionine sulfoximide in isolated rat hepatocytes. This suggests that it enhances GSH oxidation or conjugation, without affecting glutamylcysteine synthetase or GSH synthesis (Garrido et al.,Pharmacology and Toxicology 69, 9-12 (1991)).
- Furthermore, silybin was found to be a potent, non-toxic, inhibitor of glutathione-S-transferase (Bartholomeus et al.,Xenobiotica 24, 17-24, (1994)). This observation leads to the conclusion that, although silymarin might be effective as a hepatoprotective agent, secondary detoxification by conjugation to GSH, as is catalysed by GSH-transferase, is inhibited.
- Silymarin treatment (Legalon, 420 mg, 6 months) in patients with chronic alcoholic liver disease in a double blind placebo controlled trial increased the serum level of free —SH groups and the activity of GSH peroxidase. Other clinical trials confirm the hepatoprotective effect of standardised Silybum extracts.
- RO 102689 (Intr. Medicamente Biofarm) discloses the extraction of silymarin from armurariu fruit. Said extract shall be useful in the treatment of active chronic hepatitis, cirrhosis of the liver and for the protection of liver cells during administration of hepatoxic agents.
-
- Several iridoid glucosides have been isolated fromP. kurrooa, most of them conjugates of catalpol with either benzoyl- or cinnamoyl-derived side chains.
- Picroliv is a standardised fraction ofPicrorhiza kurrooa containing the iridoid glycosides picroside I and kutkoside in a ratio of 1:1.5 to 1:2 (50-70%) and a mixture of cucurbitacin glycosides (4-5%) (US-A 5145955). Picroside II has also been isolated from Picrorhiza kurrooa and 50 mg/kg p.o. in mice treated with CCl4 showed a hepatoprotective activity (DE-A 2203884).
- Picroliv has been tested in a number of liver damage models in vitro and in vivo. These studies have demonstrated its antihepatotoxic, hepatoregenerative, choleretic, and hypolipidemic activities (reviewed by Dhawan,Medicinal Chemistry Research 5, 595-605, (1995)). Hepatoregenerative effects were associated with an increased recovery of the liver anti-oxidant system after partial hepatectomy or carbon tetrachloride-induced liver damage of Picroliv-treated rats. Furthermore, Picroliv significantly reversed paracetamol-induced biochemical changes in several liver cell markers after oral administration to rats (6 and 12 mg/kg) for 7 days. Injection of carbon tetrachloride in rats induced a drastic impairment of the hepatic mixed-function oxidase system, as indicated by several drug-metabolising enzymes such as glutathione-S-transferase and reduced glutathione. Administration of Picroliv (6 mg/kg) for 7 days significantly prevented liver damage (Rastogi et al., Drug Development Research 41, 44-47, (1997)). Picroliv, given to rats during the last 15 days (12 mg/kg/day p.o.) of a 45 days exposure to alcohol, prevented the decrease of superoxide dismutase, catalase, glutathione-S-transferase, and the level of reduced glutathione (Rastogi et al., 1196). Picroliv (6 mg/kg/day p.o.) recovered the depletion of reduced glutathione level and the inhibition of glutathione-S-transferase, glutathione reductase, and glutathione peroxidase activities in the livers of mice infected with Plasmodium berghei. (Furthermore, Picroliv recovered the decreased levels of cysteine, sulphydryl groups and glutathione synthesis by suppressing the enhanced activation of Υ-glutamyl transpeptidase in mice infected with Plasmodium berghei. Pretreatment with the ethanol extract of Picrorhiza kurrooa (50 mg/kg/day, p.o.) prevented the decrease of glutathione peroxidase and glutathione transferase activity, and the decrease of reduced glutathione in rats with galactosamine-induced liver damage
- Apocynin, an acetophenone isolated fromP. kurrooa, enhances intracellular GSH synthesis, mediated by the increased expression of Υ-GCS mRNA and enzyme activity through activation of transcription factor AP-1 (Lapperre et al., Febs Letters 443, 235-9, (1999)).
-
- Pretreatment with a lignan-enriched extract ofSchisandra chinensis (1.6 g/kg p.o.) enhanced the hepatic glutathione status and protected against physical exercise-induced muscle damage in rats (Ko et al., Phytotherapy Research 10, 450-452, (1996)). Treatment of rats with extract from Schisandra chinensis (1.6 g/kg/day p.o.) increased the hepatic GSH level and activities of GSH reductase, G6PDH, and decreased the susceptibility of hepatic tissue homogenates to peroxide-induced GSH depletion; pretreating rats with these extracts (0.2-3.2 g/kg p.o.) dose-dependently protected against CCl4-induced GSH-depletion and oxidative hepatocellular damage. These data were confirmed by other experiments, showing that Schisandra chinensis extract (1.6 g/kg/day p.o.) increases hepatic GSH levels, GSH reductase and GSH-transferase activities and prevents liver damage in rats with aflatoxin- and cadmium-induced liver damage. Pretreatment of schisanhenol and schizandrin B (200 mg/kg) to mice with ethanol-induced liver peroxidation increased dismutase and catalase activity, while GSH-peroxidase activity was unaffected. Treatment of schisandrin B (3 mmol/kg/day p.o.) increased the mitochondrial GSH level and reciprocally decreased GSSG level, elevating the GSH/GSSG ratio, and increased mitochondrial GSH reductase activity. These effects were more pronounced in CCl4-intoxicated mice, providing protection against liver damage. BCNU, a specific inhibitor of GSH reductase, however, did not affect the protective activity, although it inhibited GSH reductase activity, suggesting that the enhancement of GSH reductase activity by Schisandrin B is not a primary factor of hepatoprotection.
- The direct antioxidants are radical scavengers by their chemical composition or interfere with the formation of oxygen radicals. The antioxidants most commonly known for this function are vitamin C, vitamin E and flavonoids. Catechins from green tea and curcumin have similar effects and enhance the antioxidant activity.
- Selenium is a component of glutathione peroxidase in erythrocytes and other tissues. Glutathione peroxidase reduces hydrogen peroxide to water. Selenium is thought to be well-absorbed both as inorganic selenium salts and organic selenium compounds. A 200 μg/day supplement for 2 months in selenium-deficient patients with alcoholic cirrhosis significantly improved plasma selenium levels and glutathione peroxidase but had no effect on peroxidative parameters.
- Zinc has a role in protection against oxygen radical damage, being an essential component of cytoplasmic superoxide dismutase. Zinc ions also bind to sulphydryl groups in proteins, protecting them against oxidation. Most (80-85%) plasma zinc is bound to albumin, 15% to alpha2-macroglobulin and <2% to RBP. Plasma zinc levels are depressed by infections and other stressors, probably due to systemic redistribution mediated by metallothionein, and perhaps because plasma albumin levels are reduced in stress.
- Copper is an essential part of many enzymes which are involved in protection against free radical damage, e.g. cytochrome oxidase, lysyl oxidase, Zn/Cu superoxide dismutase. About 30% of dietary copper is absorbed, and there is some evidence that this increases in deficiency. Dietary deficiency is extremely rare. Over 80% of plasma copper is bound to ceruloplasmin (a positive acute phase protein that increases in inflammatory conditions). Free copper ions (unlikely in normal conditions but may occur in the case of copper excess) are a major source of oxygen radicals.
- Manganese is part of a number of metalloenzymes, including mitochondrial pyruvate carboxylase, superoxide dismutase and acetyl CoA carboxylase.
- It is a primary object of the present invention to provide a method of increasing the presence of glutathione in cells including the prevention or treatment of impaired liver function by administering a certain combination of components to a mammal.
- It is a further object of the present invention to provide improved compositions for increasing the presence of glutathione in cells including the prevention or treatment of impaired liver function.
- It was surprisingly found that a combination of components is required for providing an optimal protection against liver damage. It was found that, for this purpose, a combination is required with components that enhance the glutathione status of the cells. In order to achieve this, components are administered which are precursors for the endogenous glutathione production. Together therewith components are administered which enhance the endogenous glutathione biosynthesis and which enhance the regeneration of oxidised glutathione, and/or enhance the glutathione-mediated conjugation.
- The present invention provides a method of increasing the presence of glutathione in cells including the prevention or treatment of impaired liver function and novel dietetic or pharmaceutical compositions for said purpose comprising in combination at least a) one precursor of glutathione which is selected from the group consisting of cysteine and functional equivalents containing said amino acid, b) one enhancer of the glutathione biosynthesis, and c) a third component which is either selected from lignans or which is a combination c1) of an enhancer of glutathione regeneration and c2) of an enhancer of the glutathione-mediated conjugation.
- It was found that the ability to detoxify is crucial for liver health in general. If the capacity of detoxification is reduced, the liver itself becomes toxified by all the endo- and exo-toxins it would normally neutralise.
- As already pointed out above many drugs and toxins can be detoxified by conjugation with glutathione. If the detoxifying capacity via GSH of the body (liver) is exceeded other detoxification pathways will be used to a greater extent. The overall clearance will however be slower whereby body parts can be damaged which are exposed too heavily. Said parts can be for instance the liver, the respiratory tract, the gastrointestinal tract, and the skin. This could lead to respiratory diseases like COPD, emphyseme, CARA, and cancer, and liver diseases like fatty liver, cirrhosis, hepatitis and liver cancer.
- In addition many people are exposed to toxic compounds that require an adequate glutathione metabolism. This applies for instance to people who live in polluted areas (radiation, numerous halogenated, nitrated chemicals), who work with dangerous chemicals (organophosphorus insecticides or halogenated solvents) and who smoke cigarettes. Also during chronic inflammation of tissue, which may occur in the case of arthritis or inflammatory bowel disease, the glutathione levels in the inflamed tissues are often depleted. Also in this case a further stimulation of the endogenous glutathione production will be advantageous.
- The method and the compositions of the present invention can treat and/or prevent the above mentioned diseases. According to the invention the glutathione presence or the glutathione status, respectively, in the cells is increased or improved, respectively. This applies in particular for the treatment and/or prevention of impaired liver function.
- The present invention is applicable for mammals including human beings and animals, for instance birds. Several diseases here described can occur during intensive animal breeding due to the consumption of an unbalanced feed diet. Liver problems occur due to the excessive amount of fats of inferior quality or the consumption of waste products of the human food industry which for some reason have become contaminated or comprise too high levels of anti-nutritional factors. This happens predominantly in pig and poultry breeding.
- According to the present invention a glutathione precursor a) is administered in a certain minimum amount. Said precursor a) is either cysteine or one or more functional analogue(s) containing said amino acid cystelne or a combination of both. Said functional analogues are for instance salts and common esters of cysteine, especially of the L-isomer, N-alkylated derivatives of cysteine, such as N-acetyl cysteine (NAC), cysteine-rich proteins and peptides, such as some proteins from whey or egg, and cystathionine, both in reduced or oxidised form Glutathione itself in reduced or oxidised form can also increase glutathione tissue levels. When methionine or S-adenosylmethionine (SAM) are used as cystein analogues the risk for elevated cystein levels is high in animals including men suffering from impaired liver function. In case said compounds are used as cystein analogues at least folic acid, vitamin B6 and/or zinc should be present in addition. Preferably all three compounds are present in amounts that exceed the recommended daily amounts.
- The Glutathione precursor used according to the invention can be a single species or a mixture of different components or species, respectively. The minimum amount of the precursor a) administered per day is at least 100 mg cysteine, calculated as free amino acid. The minimum amount is preferably at least 200 mg per day. The maximum amount of cysteine should not exceed 2000 mg. The absolute amounts of the equivalents can be easily calculated by using the molar weight of the above mentioned amino acid.
- The precursor of glutathione a) is administered together with an enhancer of the glutathione biosynthesis b) and together with a third component c) described below. In a simple embodiment of the invention the above mentioned components a) b) and c) are administered or contained in the compositon of the invention.
- The third component c) administered is either one or more lignans or a combination of an enhancer of glutathione regeneration c1) and of an enhancer of the glutathione mediated conjugation c2). In this context it should be noted that lignans can act as an enhancer of glutathione regeneration c1) as well as an enhancer of the glutathione mediated conjugation c2). Consequently, according to a first embodiment of the present invention, the third component c) can consist of one lignan alone or a mixture of different lignans. According to a second embodiment of the invention the third component c) can be a combination of one or more lignans either with one enhancer or more enhancers of the glutathione biosynthesis c1) which is or are different from a lignan, or with one enhancer or more enhancers of the gutathione-mediated conjugation c2) which is or are different from a lignan. According to a third embodiment of the invention the third component c) can be a combination of one enhancer or more enhancers of the glutathione biosynthesis c1) which is or are different from a lignan with one enhancer ore more enhancers of the gutathione-mediated conjugation c2) which is or are also different from a lignan. According to a fourth embodiment of the invention the third component c) can be a combination of i) one enhancer or more enhancers of the glutathione biosynthesis c1) which is or are different from a lignan, ii) one enhancer or more enhancers of the gutathione-mediated conjugation c2) which is or are also different from and of iii) one lignan or more lignans.
- According to a preferred embodiment the enhancer of the glutathione biosynthesis b) contains apocynin or analogues.
- Apocynin can be isolated from plants such as Iris species (Iridaceae) or from the rhizome of Apocynam cannabinum or other Apocynaceae.
- More preferably the enhancer of the glutathione biosynthesis b) is a preparation obtained fromPicrorhiza species; even more preferably the enhancer of the glutathione biosynthesis b) is selected from the group consisting of an extract of Picrorhiza kurrooa and an extract of Picrorhiza schrophulariiflora, whereby said extract contains most preferably 0.01 to 100 mg per day apocynin or analogues.
- The enhancer of glutathione regeneration c1) is preferably selected from the group consisting of preparations rich in silymarin, such as extracts fromSilybum marianum or armurariu fruit, and preparations rich in schisandrins, such as extracts from Schisandra species; and the enhancer of glutathione-mediated detoxification process c2) is preferably selected from the group consisting of preparations rich in iridoid glycosides, especially extracts from Picrorhiza species, and preparations rich in Schisandrins such as extracts from Schisandra species.
- The preparation ofPicrorhiza species is preferably an extract from Picrorhiza kurrooa or Picrorhiza scrophulariiflora (also known as Neopicrorhiza scrophulariiflora), which contains preferably 1-100 mg of total iridoid glycosides, in particular 1 to 100 mg picrosides, more preferably 1 to 50 mg picroside II, for example about 6 mg picroside II, and 0.01-100 mg apocynin.
- According to the invention, analogues of apocynin may be used instead of or in addition to apocynin. Such analogues are in particular those in which the 4-hydroxy group is etherified, especially with a sugar moiety. The analogue in which the sugar moiety is β-D-glucose is commonly known as androsin.
- The preparation ofSilybum marianum is preferably an extract containing 10-1000 mg silymarin, more preferably 175 mg of an extract containing 140 mg of silymarin.
- The preparation ofSchisandra species is preferably an extract from Schisandra chinensis or Schisandra sphenanthera containing 0.1-100 mg of lignans, in particular 0.1 to 100 mg schisandrins, more preferably 11 to 70 mg schisandrins, for example about 5 mg schisandrins.
- The different components a), b), c), c1), and, c2) are known and described above. Several traditionally used herbs, e.g. Milk thistle, Picrorhiza and Schisandra can be used, which are known to exhibit liver protective activities, and induce or enhance the endogenous glutathione production. This endogenous antioxidant plays a central role in the metabolisation and elimination of toxins. According to the present invention the GSH status in the liver is increased, and in addition, the enzyme Υ-glutamylcysteine synthetase, responsible for GSH synthesis, is enhanced as well.
- Therefore, the present invention includes precursors and cofactors important for glutathione synthesis, compounds that enhance glutathione regeneration, and compounds that induce the glutathione-mediated detoxification process.
- Preferably, direct antioxidants like vitamin C, E, and flavonoids, and enzymatic antioxidants like selenium, zinc, copper, and manganese enhancing the antioxidant activity of the liver can be present in addition according to the present invention. This is preferred since several toxins are capable of exhibiting oxidative damage due to the formation of oxygen radicals.
- Enzymatic antioxidants are in particular components that improve the activity of glutathione peroxidase or superoxide dismutase. Selenium can be used as selenium salt and preferably as selenium yeast that provides per daily dose 10-200 mcg selenium. Zinc can be present as an inorganic or organic zinc salt, such as ZnO providing preferably 0.1-30 mg zinc per daily dose. Copper can be present as a copper salt, providing preferably 0.1-8 mg copper per daily dose. Manganese can be present as a manganese salt, providing preferably 0.1-20 mg manganese per daily dose.
- Furthermore, the composition can contain at least one compound that further enhances the glutathione status of the liver, as a cofactor in the biosynthesis of precursors of glutathione. Such a compound is selected from the group consisting of riboflavin, preferably 0.1-200 mg riboflavin, vitamin B66, preferably 0.1-200 mg vitamin B6, vitamin B12, preferably 0.1-3000 mcg vitamin B12. and folic acid or folate, preferably 10-1000 mcg folic acid. Preferred sources of vitamin B6 and vitamin B12 are pyridoxine and cyanocobalamine, respectively.
- In addition. the composition can contain at least one component that enhances the antioxidant function by directly scavenging reactive oxygen species or by interfering with their formation. Such a component is selected from the group consisting of vitamin C, preferably 10-1000 mg vitamin C, vitamin E, preferably 1-800 mg α-TE, flavonoids, preferably an extract ofMatricaria recutita containing 1-100 mg apigenin, catechins, preferably an extract of Camellia sinensis containing 1-500 mg catechins, and curcuminoids, preferably an extract of Curcuma longa containing 1-1000 mg curcumin.
- As already pointed out above the present invention applies also to animals and in particular to pig and poultry breeding. In this case the components used according to the present invention can be present in the extracts of plants which are preferably used in animal feed. Said components can also be included in a premix for blending with regular animal feed. The premix is preferably based on whey proteins as source of the glutathione precursor a).
- The compositions of the invention can have a form that is normally used for the administration of a food or of a food supplement. They can be present for instance as powders, liquids. emulsions, bars, tablets, and capsules which can be packaged in cartons, cans, sachets, bottles, bags (tea bags) and can be prepared according to methods known in the art.
- A composition according to the invention in the form of a tablet contains for instance 300 mg glutathione, 20 mg apocynin and 5 mg schisandrins.
- The invention is further described by the following, non limiting examples.
- The following composition was mixed and prepared in a pill.
Amount per serving (serving size 3 tablets) amount unit Silybum marianum (milk thistle) fruit extract 175 mg [providing silymarin (80%) 140 mg] Camellia sinensis (green tea) leaf extract 28.5 mg [providing catechins 20 mg] Curcuma longa (turmeric) root extract 10.5 mg [providing curcumin 10 mg] Picrorhiza kurrooa rhizome extract 120 mg [providing picrosides 6 mg] Schisandra chinensis fruit extract 55.6 mg [providing schisandrins 5 mg] Matricaria recutita (camomile) flower extract 625 mg [providing apigenin 15 mg] vitamin C (ascorbic acid) 54.2 mg (providing ascorbic acid 50 mg] vitamin E acetate 6.8 mg succinate 10.9 mg [providing tocopherols 15.5 [U] Selenium yeast 14.7 mg (prvoviding selenium 28 mcg Zinc oxide 3.8 mg [providing zinc 3 mg Cupric oxide 0.58 mg [providing copper 0.45 mg] Manganese gluconate dihydrate 7.2 mg [providing manganese 0.8 mcg] vitamin B12 1.3 mg [providing cyanocobolamine 1.6 mcg] folic acid 0.27 mg [providing folate 200 mcg] N-acetylcysteine 202 mg [providing N-acetylcysteine 200 mg] - Three tablets were administered daily, preferably combined with an additional multivitamin, to treat deprived liver function.
-
Amount per daily dose amount unit Silybum marianum (milk thistle) fruit extract 175 mg Curcuma longa (turmeric) root extract 10.5 mg Picrorhiza kurrooa rhizome extract 360 mg Schisandra chinensis fruit extract 55.6 mg Matricaria recutita (camomile) flower extract 625 mg N-acetylcysteine 600 mg -
Amount per daily dose amount unit Silybum marianum (milk thistle) 175 mg Picrorhiza kurrooa 360 mg N-acetylcysteine 600 mg -
Amount per daily dose amount unit Silybum marianum (milk thistle) 175 mg Picrorhiza kurrooa 120 mg Schisandra chinensis 55.6 mg Selenium yeast (about 0.2% selenium) 15 mg Zinc oxide 3.8 mg Copper oxide 600 mcg Manganese gluconate 7.2 mg N-acetylcysteine 200 mg -
Amount per daily dose Amount unit Silybum marianum (milk thistle) 175 mg Picrorhiza kurrooa 120 mg vitamin B2 (riboflavin) 1.25 mg vitamin B6 (pyridoxine) 1.3 mg vitamin B12 premix (1% 0.18 mg cyanocobalamin) folic acid (monoglutamate) 200 mcg N-acetylcysteine 1000 mg -
Amount per daily dose amount unit Silybum marianum (milk thistle) 175 mg Camellia sinensis (green tea) 28.5 mg Curcuma longa (turmeric) 10.5 mg Picrorhiza kurrooa 120 mg Schisandra chinensis 55.6 mg Matricaria recutita (camomile) 625 mg vitamin C (ascorbic acid) 50 mg Alfa-tocopherol (vitamin E) 10.4 IU N-acetylcysteine 200 mg
Claims (32)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/284,158 US20030054048A1 (en) | 2000-08-16 | 2002-10-31 | Method of increasing the presence of glutathione in cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/639,469 US6495170B1 (en) | 2000-08-16 | 2000-08-16 | Method of increasing the presence of glutathione in cells |
US10/284,158 US20030054048A1 (en) | 2000-08-16 | 2002-10-31 | Method of increasing the presence of glutathione in cells |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/639,469 Division US6495170B1 (en) | 2000-08-16 | 2000-08-16 | Method of increasing the presence of glutathione in cells |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030054048A1 true US20030054048A1 (en) | 2003-03-20 |
Family
ID=24564219
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/639,469 Expired - Lifetime US6495170B1 (en) | 2000-08-16 | 2000-08-16 | Method of increasing the presence of glutathione in cells |
US10/284,158 Abandoned US20030054048A1 (en) | 2000-08-16 | 2002-10-31 | Method of increasing the presence of glutathione in cells |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/639,469 Expired - Lifetime US6495170B1 (en) | 2000-08-16 | 2000-08-16 | Method of increasing the presence of glutathione in cells |
Country Status (2)
Country | Link |
---|---|
US (2) | US6495170B1 (en) |
DE (1) | DE10151148A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060263385A1 (en) * | 2005-05-17 | 2006-11-23 | Fran Gare | Composition to relieve side effects of alcohol intoxication |
US20070099843A1 (en) * | 2005-10-31 | 2007-05-03 | David Jiang | Nutritional supplement for the enhancement of the health of the liver |
US20100234461A1 (en) * | 2003-07-03 | 2010-09-16 | Hill's Pet Nutrition, Inc. | Compositions For Improved Oxidative Status In Companion |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020110605A1 (en) * | 2000-12-11 | 2002-08-15 | Ryusuke Nakagiri | Liver function protecting or improving agent |
PT1379146E (en) * | 2001-03-23 | 2009-09-02 | Nutricia Nv | Preparation for the prevention and/or treatment of altered bone metabolism |
EP1302115A1 (en) * | 2001-10-16 | 2003-04-16 | Societe Des Produits Nestle S.A. | Use of cystathionine |
US7407986B2 (en) | 2001-12-18 | 2008-08-05 | Brassica Foundation For Chemoprotection Research, Inc. | Prevention and treatment of oxidative stress disorders by glutathione and phase II detoxification enzymes |
US6949586B2 (en) * | 2002-02-11 | 2005-09-27 | Council Of Scientific Research | Synergistic composition of trans-tetracos-15-enoic acid and Apocynin and method of treatment for hepatotoxicity |
US6592908B1 (en) | 2002-09-23 | 2003-07-15 | Albert Crum | Nutritional or therapeutic compositions |
DE10360954B3 (en) * | 2003-12-23 | 2005-08-18 | Esparma Gmbh | Use of silibinin, its salts and / or its prodrugs together with α-lipoic acid for the treatment of chronic obstructive pulmonary diseases |
EP2266586A1 (en) * | 2004-03-23 | 2010-12-29 | Lifeline Nutraceuticals Corporation | Compositions and method for alleviating inflammation and oxidative stress in a mammal |
US9265808B2 (en) | 2004-03-23 | 2016-02-23 | Lifeline Nutraceuticals Corporation | Compositions for alleviating inflammation and oxidative stress in a mammal |
US8895084B2 (en) * | 2004-12-23 | 2014-11-25 | Colgate-Palmolive Company | Oral care composition containing extract of unoxidized Camellia |
US20080138483A1 (en) * | 2005-02-09 | 2008-06-12 | Kevin Meehan | Animal feed composition for increased bioactivity and production of glutathione peroxidase and superoxide dismutase |
AU2006228996B2 (en) * | 2005-03-31 | 2011-03-31 | Newsouth Innovations Pty Limited | Process for the production of gamma-glutamylcysteine |
JP5221336B2 (en) * | 2005-03-31 | 2013-06-26 | ニューサウス イノベイションズ ピーティーワイ リミテッド | Process for producing γ-glutamylcysteine |
EP2025335A1 (en) * | 2007-08-16 | 2009-02-18 | InterMed Discovery GmbH | Extracts with liver-X-receptor modulators, compounds and their use in weight control and treatment of disorders of lipid metabolism |
EP2854798A4 (en) * | 2012-05-24 | 2016-05-11 | Mograbi Josef | Compositions comprising isosilybin b for amelioration and prevention of drug- induced toxicity |
CA3153463A1 (en) | 2012-10-29 | 2014-05-08 | The University Of North Carolina At Chapel Hill | Methods and compositions for treating mucosal tissue disorders |
US11197917B2 (en) | 2017-12-01 | 2021-12-14 | ByHeart, Inc. | Formulations for nutritional support in subjects in need thereof |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5747459A (en) * | 1991-02-04 | 1998-05-05 | Nestec, Ltd. | Method for insuring adequate intracellular glutathione in tissue |
US5929038A (en) * | 1992-07-15 | 1999-07-27 | Choongwae Pharmaceutical Co., Ltd. | Pharmaceutical preparations which inhibit hepatitis B virus (HBV) replication |
US6013663A (en) * | 1997-04-02 | 2000-01-11 | Sankyo Company, Limited | Dithiolan derivatives, their preparation and their therapeutic effect |
US6030950A (en) * | 1987-07-09 | 2000-02-29 | Ohlenschlaeger; Gerhard | Pharmaceutical therapeutic use of glutathione derivative |
US6132727A (en) * | 1994-08-22 | 2000-10-17 | Rohde, Jr.; Rodger R. | Enzyme-activated botanical food supplement composition |
US6197295B1 (en) * | 1996-09-25 | 2001-03-06 | Viva America Marketing Corporation | Dietary supplementation with, and methods for administration of yeast-derived selenium product |
US6262019B1 (en) * | 1998-04-30 | 2001-07-17 | Vit-Immune, L. C. | Method of treatment of glutathione deficient mammals |
US6268336B1 (en) * | 1996-06-20 | 2001-07-31 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for treatment of hepatic diseases |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2203884A1 (en) * | 1972-01-27 | 1973-08-02 | Schwabe Willmar | Extracting glycosides from picrorrhiza kurroa-useful - for treating liver disorders |
JPS60258115A (en) * | 1984-06-04 | 1985-12-20 | Hiroshi Hikino | Improver for liver disorder |
DE3784905T2 (en) * | 1986-07-07 | 1993-08-05 | Teijin Ltd | GAMMA-L-GLUTAMYL-L-CYSTEIN ETHYL ESTER AND MEDICINAL PRODUCTS CONTAINING THIS AS AN ACTIVE AGENT. |
DE3628010A1 (en) * | 1986-08-19 | 1988-02-25 | Astra Chem Gmbh | Pharmaceutical for treatment of hypertonia - contains selenium, thus also compensating for selenium deficiency |
US6059766A (en) * | 1998-02-27 | 2000-05-09 | Micro Therapeutics, Inc. | Gynecologic embolotherapy methods |
JP2000302784A (en) * | 1999-04-22 | 2000-10-31 | Toyama Chem Co Ltd | Apocynins, and prophylactic and therapeutic agent containing the same |
-
2000
- 2000-08-16 US US09/639,469 patent/US6495170B1/en not_active Expired - Lifetime
-
2001
- 2001-10-17 DE DE10151148A patent/DE10151148A1/en not_active Withdrawn
-
2002
- 2002-10-31 US US10/284,158 patent/US20030054048A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6030950A (en) * | 1987-07-09 | 2000-02-29 | Ohlenschlaeger; Gerhard | Pharmaceutical therapeutic use of glutathione derivative |
US5747459A (en) * | 1991-02-04 | 1998-05-05 | Nestec, Ltd. | Method for insuring adequate intracellular glutathione in tissue |
US5929038A (en) * | 1992-07-15 | 1999-07-27 | Choongwae Pharmaceutical Co., Ltd. | Pharmaceutical preparations which inhibit hepatitis B virus (HBV) replication |
US6132727A (en) * | 1994-08-22 | 2000-10-17 | Rohde, Jr.; Rodger R. | Enzyme-activated botanical food supplement composition |
US6268336B1 (en) * | 1996-06-20 | 2001-07-31 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for treatment of hepatic diseases |
US6197295B1 (en) * | 1996-09-25 | 2001-03-06 | Viva America Marketing Corporation | Dietary supplementation with, and methods for administration of yeast-derived selenium product |
US6013663A (en) * | 1997-04-02 | 2000-01-11 | Sankyo Company, Limited | Dithiolan derivatives, their preparation and their therapeutic effect |
US6262019B1 (en) * | 1998-04-30 | 2001-07-17 | Vit-Immune, L. C. | Method of treatment of glutathione deficient mammals |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100234461A1 (en) * | 2003-07-03 | 2010-09-16 | Hill's Pet Nutrition, Inc. | Compositions For Improved Oxidative Status In Companion |
US8835497B2 (en) | 2003-07-03 | 2014-09-16 | Hill's Pet Nutrition, Inc. | Compositions for improved oxidative status in companion animals |
EP1641352B2 (en) † | 2003-07-07 | 2019-06-19 | Hill's Pet Nutrition, Inc. | Compositions for improved oxidative status in cats |
US20060263385A1 (en) * | 2005-05-17 | 2006-11-23 | Fran Gare | Composition to relieve side effects of alcohol intoxication |
US20070099843A1 (en) * | 2005-10-31 | 2007-05-03 | David Jiang | Nutritional supplement for the enhancement of the health of the liver |
Also Published As
Publication number | Publication date |
---|---|
DE10151148A1 (en) | 2002-10-10 |
US6495170B1 (en) | 2002-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6495170B1 (en) | Method of increasing the presence of glutathione in cells | |
Preetha et al. | Lupeol ameliorates aflatoxin B1-induced peroxidative hepatic damage in rats | |
Lee et al. | Rutin and quercetin, bioactive compounds from tartary buckwheat, prevent liver inflammatory injury | |
Maldonado et al. | Antioxidant S-allylcysteine prevents gentamicin-induced oxidative stress and renal damage | |
Pingili et al. | A comprehensive review on hepatoprotective and nephroprotective activities of chrysin against various drugs and toxic agents | |
Hewawasam et al. | Protective effect of Asteracantha longifolia extract in mouse liver injury induced by carbon tetrachloride and paracetamol | |
Faremi et al. | Hepatoprotective potentials of Phyllanthus amarus against ethanol-induced oxidative stress in rats | |
Lin et al. | Hepatoprotective activity of Chhit-Chan-Than extract powder against carbon tetrachloride-induced liver injury in rats | |
Mohebbati et al. | Effects of standardized Zataria multiflora extract and its major ingredient, Carvacrol, on Adriamycin-induced hepatotoxicity in rat | |
US10039776B2 (en) | Hepato-protective beverage composition | |
Perumal et al. | Effect of diosmin on apoptotic signaling molecules in N-nitrosodiethylamine-induced hepatocellular carcinoma in experimental rats | |
Saravanan et al. | Antioxidant effect of 2‐hydroxy‐4‐methoxy benzoic acid on ethanol‐induced hepatotoxicity in rats | |
Chaudhary et al. | Chemopreventive potential of an Indian medicinal plant (Tinospora cordifolia) on skin carcinogenesis in mice | |
EP1425043A1 (en) | Method of increasing the presence of glutathione in cells | |
Abd-Allah et al. | The possible protective effect of ginger against intestinal damage induced by methotrexate in rats | |
Devi et al. | Protective effect of Premna tomentosa extract (L. verbanacae) on acetaminophen-induced mitochondrial dysfunction in rats | |
Nithiya et al. | Protective effect of phloretin on hyperglycemia mediated oxidative stress in experimental diabetic rats | |
Pervin et al. | Lead toxicity: an overview of its pathophysiology and intervention strategies | |
AU2002212244A1 (en) | Method of increasing the presence of glutathione in cells | |
Shah et al. | In vivo and In vitro Antioxidant and Hepatoprotective effects of Classical ayurvedic formulation Punarnavashtak kwath against Ethanol induced hepatotoxicity | |
Minamiyama et al. | Amelioration of cisplatin toxicity by a fermented grain food product | |
Mullen et al. | Potential new therapies for alcoholic liver disease | |
Mutlag et al. | Study the possible hepatoprotective effect of different doses of Ammi majus seeds’ extract against CCl4 induced liver damage in rats | |
Adelina | Clinical Studies of Silymarin as a Protective Agent Against Liver Damage Caused by Anti-TB Drugs, Methotrexate, and in Cases of Chronic Hepatitis C and Diabetes Mellitus | |
Bakare et al. | Aluminum chloride-induced oxidative damage to serum and combined intervention of ascorbic acids and massularia acuminata on selected markers of in vivo antioxidant enzymes in wistar rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: LEHMAN COMMERCIAL PAPER INC., AS ADMINISTRATIVE AG Free format text: SECURITY AGREEMENT;ASSIGNOR:GENERAL NUTRITION CORPORATION;REEL/FRAME:014934/0916 Effective date: 20031205 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: GENERAL NUTRITION CORPORATION, PENNSYLVANIA Free format text: RELEASE OF SECURITY INTEREST AT REEL/FRAME NO. 14934/0916;ASSIGNOR:LEHMAN COMMERCIAL PAPER, INC.;REEL/FRAME:019134/0223 Effective date: 20070316 |
|
AS | Assignment |
Owner name: GENERAL NUTRITION INVESTMENT COMPANY, ARIZONA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JPMORGAN CHASE BANK, N.A.;REEL/FRAME:025905/0054 Effective date: 20110304 |